Amplia Therapeutics (ASX: ATX) chief scientific officer Mark Devlin joins Small Caps to discuss the latest achievements made in the company's research and development of its anti-cancer drug AMP945. The pharmaceutical company revealed new data from its recent phase one clinical trial that shows the ability of AMP945 to inhibit focal adhesion kinase (FAK) in healthy human volunteers when administered as an oral capsule. FAK activity was measured in skin samples taken before and after doses of the drug and showed a reduction in activity can be achieved at safe and well-tolerated dosage levels. The data will be used to further refine the doses of AMP945 to be used in an upcoming phase two clinical trial in patients with pancreatic cancer. It will also provide guidance for the phase two trial in pulmonary fibrosis planned for the second half of 2022.

Articles:

https://smallcaps.com.au/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase/

https://smallcaps.com.au/amplia-therapeutics-secures-renowned-oncology-drug-development-expert-clinical-advisor/

For more information:

https://smallcaps.com.au/stocks/ATX/